Novo’s Business Plan For Tresiba Insulin Includes ‘Moderate’ Price Premium
Executive Summary
Reduced risk of hypoglycemia compared to competing long-acting insulin is not in Tresiba’s FDA label, at least not yet, but Novo Nordisk sees room for differentiation in duration and dosing flexibility.